Reading the LS "press release" right now....

This part jumped out....: : Two years ago we split the company. Many of our compounds went into Zenith Epigenetics Corp., which spun out of Resverlogix to commercialize its epigenetic platform technology. Zenith started programs in oncology and autoimmune diseases. However, during the last few months we have brought some of those compounds back into Resverlogix because of our newer understanding of the mechanism of action. Consequently, we have thousands of compounds in Resverlogix right now, including two very solid follow-on compounds for cardiovascular and renal purposes.

So Zenith has moved some compounds back to Resverlogix...so nice to finally let us know.

And then of course is the orphan indication....more hints: So its a pediatric indication, and they plan to monetize it....geesh.